Estimation of fatty liver disease clinical role on glucose metabolic remodelling phenotypes and T2DM onset

• DOI: 10.1111/eci.14036
• Publication Date: 2023-06-12T03:48:40Z
• Authors: Diego Martinez‐Ur...; Ana Huerta; David Navarro‐Gon...; Laura Sánchez‐Iñigo; Alejandro Fernand...; Manuel F. Landecho; J. Alfredo Martinez; Juan C. Pastrana‐...
• Keywords: Prediabetes; Steatosis

Abstract Introduction Metabolic syndrome (MetS), prediabetes (PreDM) and Fatty Liver Disease (FLD) share pathophysiological pathways concerning type 2 diabetes mellitus (T2DM) onset. The non‐invasive assessment of fatty liver combined with PreDM MetS features screening might provide further accuracy in predicting hyperglycemic status the clinical setting putative description singular phenotypes. objective study is to evaluate describe links a widely available FLD surrogate ‐the serological biomarker Hepatic Steatosis Index (HSI)‐ previously described T2DM risk predictors, such as preDM forecasting Patients methods A retrospective ancillary cohort was performed on 2799 patients recruited Vascular‐Metabolic CUN cohort. main outcome incidence according ADA criteria. were defined ATP III criteria, respectively. steatosis index (HSI) standardized thresholds used discriminate FLD, which referred estimated (eFLD). Results more common eFLD compared those an HSI < 36 points (35% vs 8% 34% vs. 18%, respectively). Interestingly, showed effect modification prediction [eFLD‐MetS interaction HR = 4.48 (3.37‐5.97) eFLD‐PreDM 6.34 (4.67‐8.62)]. These findings supported 5 different status‐linked phenotypes increasing T2DM: Control group (1,5% incidence), (4,4% (10,6% (11,1% incidence) (28,2% incidence). provided independent capacity after adjustment for age, sex, tobacco alcohol consumption, obesity number SMet c‐Harrell=0.84. Conclusion Estimated using criteria (eFLD) interplay help patient through metabolic [Correction added 15 June 2023, first online publication: abstract section updated this current version.]